In leukemia, bone marrow (BM) cells from acute lymphoblastic leukemia (ALL) patients showed upregulation of E2 ubiquitin-conjugating enzyme Q2 (UBE2Q2) compared to the normal counterparts [33] and ubiquitin-conjugating enzyme E2 A (UBE2A) mutations are specifically acquired during chronic myeloid leukemia (CML) progression, resulting in a lower UBE2A activity leading to an impaired myeloid differentiation [34]. Here, UBE2Q2 is linked to leukemia.